Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $39.0752W HIGH $52.68
Volume
2.91 M
Value Traded
146.12 M
Short % Float
0.49%
Days to Cover
3.1
+0.67%Week
+3.68%1 Month
-1.52%3 Month
-9.32%6 Month
-17.69%5 Year
+45.21%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
102.03 B
EPS (TTM)
2.40
P/E Ratio
17.62
Ent. Value
122.63 B
Total Shares
2.42 B
Float Shares
2.38 B
Insiders
0.00%
Institutions
7.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SNY Catalyst Timeline
Dated clinical, regulatory and corporate events for Sanofi
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sanofi
1479Total events
23Upcoming
782Tier-1 (high impact)
2010 to 2032Coverage
Upcoming catalysts 2
Event history 50
▲Long Term DataDuvakitugClinical Data
Duvakitug maintained clinical remission, response and endoscopic improvement at Week 44 in UC
ulcerative colitissource ↗
▲Biomarker DataDuvakitugClinical Data
Duvakitug reduced inflammatory and tissue remodeling biomarkers in UC and CD
ulcerative colitis; Crohn's diseasesource ↗
▲Safety Data UpdateDuvakitugClinical Data
Duvakitug well tolerated through maintenance with no new safety concerns
ulcerative colitis; Crohn's diseasesource ↗
●Oral PresentationDuvakitugPresentation
Duvakitug LTE and biomarker data presented at UEG Week 2026 in Barcelona
ulcerative colitis; Crohn's diseasesource ↗
●Manufacturing MilestoneCMC / Inspection
Sanofi breaks ground on new insulin manufacturing facility in Frankfurt, Germany
▲Partnership / LicenseCorporate
Sanofi and Regeneron expand global antibody collaboration adding four long-acting antibodies
▲Legal / SettlementCorporate
Sanofi and Regeneron settle prior collaboration-related litigation
▲Partnership / LicenseCorporate
Sanofi and Cheplapharm announce intention to create strategic partnership for 20 mature medicines and three manufacturing sites
▲Corporate ApprovalCorporate
European Commission approved public support from German Federal Government, State of Hesse and City of Frankfurt under EU state aid framework
▲EU ApprovalMenQuadfiApprovedEx-US Regulatory
EC approved extension of indication for MenQuadfi to include infants from six weeks of age
invasive meningococcal diseasesource ↗
▲Full ResultsMenQuadfiApprovedClinical Data
MET58 pivotal study data supporting EU approval
invasive meningococcal diseasesource ↗
▲Pediatric Exclusivity GrantedMenQuadfiApprovedFDA Decision
Paediatric Investigation Plan compliance statement received from EMA
invasive meningococcal diseasesource ↗
▼Program DiscontinuationAmlitelimabDiscontinuedCorporate
Discontinuation of clinical development of amlitelimab in atopic dermatitis; decision not to submit for global regulatory reviews
moderate-to-severe atopic dermatitissource ↗
▼Trial DiscontinuedAmlitelimabDiscontinuedTrial
Wind-down of ongoing amlitelimab AD studies including ESTUARY
moderate-to-severe atopic dermatitissource ↗
▲Partnership / LicenseCorporate
Aqemia and Sanofi expand research collaboration with new target nomination and additional payment
▲FDA ApprovalFDA Decision
FDA approval of subcutaneous Sarclisa Escena for multiple myeloma across all existing IV indications
multiple myelomasource ↗
▲Full ResultsClinical Data
IRAKLIA phase 3 results: non-inferiority of SC Sarclisa Escena via OBI vs IV in combination with Pd
relapsed or refractory multiple myelomasource ↗
◆NDA SubmissionRegulatory Filing
Regulatory submission for CirCLIQ OBI in Japan under review
multiple myelomasource ↗
●FDA Filing AcceptedRegulatory Filing
Regulatory submission for CirCLIQ OBI in Japan under review
multiple myelomasource ↗
▲Topline ReadoutClinical Data
IRAKLIA phase 3 topline results: non-inferiority of SC vs IV Sarclisa
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetNexviazymeApprovedClinical Data
Nexviazyme met primary endpoint in Baby-COMET study
infantile-onset Pompe diseasesource ↗
▲Secondary Endpoint DataNexviazymeApprovedClinical Data
All secondary endpoints met in Baby-COMET study
infantile-onset Pompe diseasesource ↗
▲CHMP Positive OpinionMenQuadfiApprovedEx-US Regulatory
CHMP adopted positive opinion for MenQuadfi infant indication
invasive meningococcal diseasesource ↗
▲Partnership / LicenseCorporate
Sanofi signs MoU with Abu Dhabi Department of Health to explore vaccine innovation center
▲EU ApprovalCenrifkiApprovedEx-US Regulatory
European Commission approval of Cenrifki for SPMS without relapses
secondary progressive multiple sclerosis without relapsessource ↗
▲CHMP Positive OpinionCenrifkiApprovedEx-US Regulatory
CHMP positive opinion for Cenrifki
secondary progressive multiple sclerosis without relapsessource ↗
▲Topline ReadoutTolebrutinibApprovedClinical Data
HERCULES phase 3 topline results supporting approval
non-relapsing secondary progressive multiple sclerosissource ↗
▲Other Regulator MilestoneWayrilzApprovedEx-US Regulatory
Wayrilz approved in Japan for ITP
immune thrombocytopeniasource ↗
▲Other Regulator MilestoneSarclisaApprovedEx-US Regulatory
Sarclisa SC approved in Japan for multiple myeloma
multiple myelomasource ↗
▲Topline ReadoutSarclisaApprovedClinical Data
IRAKLIA topline results: non-inferior efficacy and PK for SC vs IV
relapsed or refractory multiple myelomasource ↗
◆FDA Filing AcceptedSarclisaApprovedRegulatory Filing
Sarclisa SC regulatory submission under review in US
multiple myelomasource ↗
▲EU ApprovalSarclisaApprovedEx-US Regulatory
Sarclisa SC approved in EU for multiple myeloma
multiple myelomasource ↗
▲FDA Filing AcceptedvenglustatFiledRegulatory Filing
FDA accepted NDA for priority review for venglustat in GD3
type 3 Gaucher diseasesource ↗
▲Priority ReviewvenglustatFiledRegulatory Filing
FDA granted priority review for venglustat NDA
type 3 Gaucher diseasesource ↗
▲Topline Readoutefdoralprin alfaClinical Data
Phase 2 ElevAATe topline data demonstrate superiority of efdoralprin alfa over standard-of-care in achieving higher fAAT levels
alpha-1 antitrypsin deficiency (AATD)-related emphysemasource ↗
▲Oral Presentationefdoralprin alfaPresentation
Oral presentation of ElevAATe phase 2 results at ATS 2026
alpha-1 antitrypsin deficiency (AATD)-related emphysemasource ↗
◆Management ChangeCorporate
Belén Garijo appointed as Director and CEO of Sanofi, effective May 1, 2026
●Management ChangeCorporate
Christel Heydemann appointed as independent board member; Frédéric Oudéa appointed Chairman of Appointments Committee
▲Oral PresentationNUVAXOVIDApprovedPresentation
COMPARE study results presented at ESCMID Global Congress
COVID-19source ↗
▲Primary Endpoint MetNUVAXOVIDApprovedClinical Data
COMPARE study met primary endpoint of systemic reactogenicity within 7 days
COVID-19source ↗
▲Primary Endpoint MetLunsekimigClinical Data
DUET phase 2a met primary and key secondary endpoints in CRSwNP
chronic rhinosinusitis with nasal polyps (CRSwNP)source ↗
▼Primary Endpoint MissedLunsekimigClinical Data
VELVET phase 2b did not meet primary endpoint in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
◆Topline ReadoutAmlitelimabDiscontinuedClinical Data
Phase 2 topline readout in celiac disease expected
celiac diseasesource ↗
▲Late-BreakerAmlitelimabDiscontinuedPresentation
Late-breaking presentation of COAST 2 results at AAD 2026
moderate-to-severe atopic dermatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How SNY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-16 | Ayvakit (avapritinib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
85
Drugs Scored
rNPV / MCap
Top Drug
Top 2%
Large Pharma(rank 14 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), converted from EUR to USD, to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Dupixent | |||
| Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B | |||
| COVID-19 and Influenza vaccines | |||
| RSV vaccines (Beyfortus) | |||
| Lantus | |||
| Toujeo | |||
| ALTUVIIIO | |||
| Meningitis, travel, and endemic vaccines | |||
| Fabrazyme | |||
| Plavix | |||
| Nexviazyme/Nexviadyme | |||
| Lovenox |
Top 12 of 34 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Frexalimab Monoclonal antibodyNCT04879628 | Multiple Sclerosis | Phase 3 | ACTIVE NOT_RECRUITING | 2,887 | Aug 23, 2027 | ||||||
| Frexalimab Monoclonal antibodyNCT06111586 | Type 1 Diabetes Mellitus | Phase 2 | ACTIVE NOT_RECRUITING | 197 | Oct 29, 2030 | ||||||
| Frexalimab Monoclonal antibodyNCT07412470 | Kidney Transplant Rejection | Phase 2 | RECRUITING | 526 | Aug 15, 2033 | ||||||
| Frexalimab Monoclonal antibodyNCT05039840 | Systemic Lupus Erythematosus | Phase 2 | ACTIVE NOT_RECRUITING | 109 | Nov 24, 2026 | ||||||
| Frexalimab Monoclonal antibodyNCT06500702 | Focal Segmental Glomerulosclerosis | Phase 2 | RECRUITING | 84 | Feb 16, 2028 | ||||||
| Brivekimig Small moleculeNCT06812988 | Type 1 Diabetes Mellitus | Phase 2 | ACTIVE NOT_RECRUITING | 84 | Apr 29, 2027 | ||||||
| Brivekimig Small moleculeNCT07170917 | Hidradenitis Suppurativa | Phase 2 | RECRUITING | 208 | Nov 23, 2029 | ||||||
| Brivekimig Small moleculeNCT06958536 | Crohn's Disease | Phase 2 | RECRUITING | 99 | Oct 17, 2029 | ||||||
| SAR442970 Small moleculeNCT06975722 | Ulcerative Colitis | Phase 2 | ACTIVE NOT_RECRUITING | 105 | Oct 17, 2029 | ||||||
| Amlitelimab Monoclonal antibodyNCT05769777 | Dermatitis Atopic | Phase 3 | ACTIVE NOT_RECRUITING | 6,940 | Jun 11, 2031 | ||||||
| Amlitelimab Monoclonal antibodyNCT06557772 | Coeliac Disease | Phase 2 | ACTIVE NOT_RECRUITING | 229 | Apr 10, 2029 | ||||||
| Itepekimab Monoclonal antibodyNCT07424144 | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | ACTIVE NOT_RECRUITING | 506 | Feb 17, 2027 | ||||||
| Lunsekimig Small moleculeNCT07793409 | Chronic Obstructive Pulmonary Disease | Phase 3 | ENROLLING BY_INVITATION | 3,392 | Jul 23, 2031 | ||||||
| Lunsekimig Small moleculeNCT06676319 | Asthma | Phase 2 | ACTIVE NOT_RECRUITING | 2,141 | Jul 19, 2027 | ||||||
| Belumosudil Small moleculeNCT06082037 | Lung Transplant Rejection | Phase 3 | RECRUITING | 180 | Oct 1, 2030 | ||||||
| Belumosudil Small moleculeMarketedNCT06143891 | Chronic Graft Versus Host Disease | Phase 3 | ACTIVE NOT_RECRUITING | 734 | Sep 29, 2028 | ||||||
| Belumosudil Small moleculeMarketedNCT07643025 | cGVHD | Phase 2 | NOT YET_RECRUITING | 53 | Nov 1, 2030 | ||||||
| Duvakitug Small moleculeNCT05668013 | Crohn Disease | Phase 3 | ACTIVE NOT_RECRUITING | 1,978 | Jan 31, 2027 | ||||||
| Duvakitug Small moleculeNCT07184996 | Ulcerative Colitis | Phase 3 | RECRUITING | 1,731 | May 9, 2028 | ||||||
| Duvakitug Small moleculeNCT07812116 | Hidradenitis | Phase 2 | NOT YET_RECRUITING | 156 | Nov 8, 2030 | ||||||
| Isatuximab Monoclonal antibodyNCT04850599 | Plasma Cell Myeloma Recurrent | Phase 3 | ACTIVE NOT_RECRUITING | 536 | Feb 21, 2029 | ||||||
| Isatuximab Monoclonal antibodyNCT04270409 | Plasma Cell Myeloma | Phase 3 | ACTIVE NOT_RECRUITING | 1,856 | Oct 21, 2033 | ||||||
| Isatuximab Monoclonal antibodyMarketedNCT05704049 | Relapsed/Refractory Multiple Myeloma | Phase 2 | ACTIVE NOT_RECRUITING | 118 | May 12, 2028 | ||||||
| Isatuximab Monoclonal antibodyNCT04643002 | Plasma Cell Myeloma Refractory | Phase 2 | RECRUITING | 322 | Apr 20, 2028 | ||||||
| Isatuximab Monoclonal antibodyMarketedNCT04891809 | Newly Diagnosed Multiple Myeloma | Phase 2 | ACTIVE NOT_RECRUITING | 198 | Dec 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every SNY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| duvakitug | ulcerative colitis and Crohn’s disease | Phase 2b | 2026-10-20 | UC clinical remission: high rates; UC clinical response: high rates; UC endoscopic improvement: high rates; CD endoscopic response: high rates; CD clinical response: high rates; CD clinical remission: high ratesRead More | UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 5.3 % (-13.1 %) | 13.82 M | 323.95 K |
SNY Institutional Ownership Trends
SNY Short Interest
Shares sold short, counted twice a month.
0.49%
Short % of Float
of tradable shares sold short
11.6M
Shares Sold Short
+9.4% vs prior count
3.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNY ranks across every disease it competes in
Competitive Position is a premium feature
See how SNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNY News
SNYUEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Teva and Sanofi presented new positive data from the RELIEVE UCCD phase 2b study at UEG Week 2026, showing that duvakitug maintained significant efficacy in treating ulcerative colitis (UC) and Crohn's disease (CD) over 44 weeks. The investigational drug demonstrated high rates of clinical remission and was well tolerated, with a safety profile consistent with earlier studies. Biomarker analyses indicated its potential to impact inflammation and tissue remodeling.
Read more →SNYISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus Project
Sanofi S.A. has been awarded the Overall Winner of the 2026 ISPE Facility of the Year Awards for its Modulus project. This recognition highlights the project's innovative design and operational flexibility in pharmaceutical manufacturing. The award was announced during the ISPE Annual Meeting & Expo in Washington, D.C., showcasing excellence in the industry. The Modulus project features advanced technologies and modular architecture to enhance vaccine and biologics production.
Read more →SNYPress Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Sanofi has commenced construction of a new insulin manufacturing facility in Frankfurt, Germany, aimed at enhancing the production capabilities for insulin. This facility, set to be operational by 2032, will utilize advanced digital technologies and is part of Sanofi's commitment to support the growing global demand for insulin. The investment reflects Sanofi's long-term strategy to ensure a reliable supply for diabetes patients worldwide.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares – September 2026
Sanofi has released information regarding the total number of voting rights and shares as of September 2026. This disclosure complies with the French Commercial Code and the regulations set by the French stock market authority. The company is registered in Paris and has a share capital of €2,415,546,786.
Read more →SNYPress Release : Availability of the aide-mémoire for Q3 2026 results
Sanofi announced the availability of the aide-mémoire for Q3 2026 results, which will assist in financial modeling. The results are set to be published on October 30, 2026. This document includes details on non-comparable items, foreign currency impact, and share count, reflecting the company's ongoing commitment to transparency.
Read more →SNYSanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
Sanofi has partnered with NBA Champion Karl-Anthony Towns to promote COVID-19 vaccination awareness, particularly focusing on the NUVAXOVID vaccine. Towns will share his personal experiences with COVID-19 to encourage eligible individuals, especially those at higher risk, to discuss vaccination options with healthcare providers. The campaign aims to address vaccine hesitancy and improve vaccination rates.
Read more →SNYPress Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron have expanded their collaboration to include multiple next-generation, long-acting immunology antibodies. The agreement includes an upfront payment of $1 billion to Regeneron, with potential future milestone payments totaling up to $7 billion. The companies will co-develop and co-commercialize four new antibodies targeting interleukin pathways, enhancing their existing partnership established over 20 years.
Read more →SNYRegeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron and Sanofi have expanded their long-term collaboration by adding multiple next-generation antibodies, including REGN20423, a long-acting IL-13 monoclonal antibody. The agreement involves an upfront payment of $1 billion and potential milestone payments of up to $7 billion. This partnership aims to enhance the development of innovative therapies for type 2 inflammatory diseases, building on their successful history with Dupixent.
Read more →SNYSanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment
Sanofi inaugurated the Charles Best Building, a new flu vaccine manufacturing facility in Toronto, marking a $925 million CAD investment. This facility will produce Fluzone® High-Dose vaccine for older adults and aims to bolster Canada's pandemic preparedness. The investment is a collaboration with various levels of government and is expected to create around 300 jobs.
Read more →SNYPress Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and Cheplapharm announced a strategic partnership to transfer 20 mature medicines and three manufacturing sites. In exchange, Sanofi will acquire a 26.4% equity stake in Cheplapharm. This collaboration aims to tailor operations for mature medicines, ensuring they continue to meet patient needs while allowing Sanofi to focus on innovation. The transition is set to begin in early 2027.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2026
Sanofi has released information regarding the total number of voting rights and shares as mandated by French regulations. The announcement includes details about the company's registered capital and its compliance with the French Commercial Code. This information is also accessible on Sanofi's official website.
Read more →SNYSanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
Sanofi has teamed up with actress Keke Palmer to promote awareness of RSV and the importance of immunization for infants. BEYFORTUS, a monoclonal antibody, is highlighted as a leading option for preventing serious RSV lung infections in babies. The campaign encourages parents to consult with healthcare providers about RSV protection ahead of the upcoming RSV season.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - July 2026
Sanofi has released information regarding the total number of voting rights and shares in compliance with French regulations. The company, registered in Paris, has a share capital of €2,415,546,786. This information is also accessible on Sanofi's official website for investors.
Read more →SNYPress Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi vaccine has received EU approval for use in infants starting from six weeks of age, expanding its previous indication for those aged 12 months and older. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use and aims to enhance protection against invasive meningococcal disease. The vaccine's immunogenicity data supports its safety and efficacy for this younger demographic.
Read more →SNYPress Release: Sanofi’s half-year financial report for 2026
Sanofi has released its half-year financial report for 2026, detailing its performance up to June 30. The report is accessible online and has been filed with regulatory bodies in France and the US. Sanofi emphasizes its commitment to research and development, focusing on improving healthcare through innovative solutions.
Read more →SNYPress Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
Sanofi has announced the discontinuation of clinical development for amlitelimab in atopic dermatitis, citing insufficient efficacy and safety evidence. Despite some positive findings in the ESTUARY phase 3 study, the drug was deemed not to offer significant improvements over current treatments. Sanofi will ensure a proper transition of care for patients involved in ongoing studies.
Read more →SNYPress Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi announced an evolution of its Executive Committee effective September 1, 2026, aimed at enhancing strategic focus across its businesses. The new leadership team includes experienced executives overseeing various functions, while some members are transitioning to different roles. This restructuring is designed to support Sanofi's next strategic chapter and improve operational integration.
Read more →SNYAqemia and Sanofi Expand Their Research Collaboration
Aqemia has announced the expansion of its research collaboration with Sanofi, which includes the nomination of a new therapeutic target and an additional payment. This collaboration, initially established in December 2023, allows Aqemia to potentially receive up to $140 million in total funding. The partnership emphasizes the integration of generative AI in drug discovery.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - June 2026
Sanofi has released information regarding the total number of voting rights and shares as required by French regulations. The announcement includes details about the company's registered share capital and its registered office. This information is accessible on Sanofi's official website for investors.
Read more →About Sanofi
BIOPHARMAWATCH ELITE PLUS
Trade the next SNY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime